Log in

Nabriva Therapeutics Stock Forecast, Price & News

-0.07 (-1.86 %)
(As of 12/4/2020 12:00 AM ET)
Today's Range
Now: $3.70
50-Day Range
MA: $0.55
52-Week Range
Now: $3.70
Volume416,591 shs
Average Volume402,378 shs
Market Capitalization$557.87 million
P/E RatioN/A
Dividend YieldN/A
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, and CONTEPO. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Nabriva Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.89 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:NBRV
Phone(531) 649-2000



Sales & Book Value

Annual Sales$9.48 million
Book Value$0.02 per share


Net Income$-82,760,000.00
Net Margins-1,682.55%


Market Cap$557.87 million
Next Earnings Date3/11/2021 (Estimated)
-0.07 (-1.86 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NBRV News and Ratings via Email

Sign-up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions

How has Nabriva Therapeutics' stock price been impacted by Coronavirus?

Nabriva Therapeutics' stock was trading at $1.21 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NBRV shares have increased by 205.8% and is now trading at $3.70.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Nabriva Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Nabriva Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Nabriva Therapeutics?

Wall Street analysts have given Nabriva Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nabriva Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Nabriva Therapeutics' next earnings date?

Nabriva Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Nabriva Therapeutics

How were Nabriva Therapeutics' earnings last quarter?

Nabriva Therapeutics plc (NASDAQ:NBRV) posted its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.01. Nabriva Therapeutics had a negative return on equity of 129.80% and a negative net margin of 1,682.55%.
View Nabriva Therapeutics' earnings history

What price target have analysts set for NBRV?

5 brokerages have issued 12-month price targets for Nabriva Therapeutics' stock. Their forecasts range from $1.00 to $7.00. On average, they expect Nabriva Therapeutics' stock price to reach $3.30 in the next year. This suggests that the stock has a possible downside of 10.8%.
View analysts' price targets for Nabriva Therapeutics

Are investors shorting Nabriva Therapeutics?

Nabriva Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 8,450,000 shares, an increase of 9.5% from the October 31st total of 7,720,000 shares. Based on an average daily volume of 1,730,000 shares, the short-interest ratio is presently 4.9 days.
View Nabriva Therapeutics' Short Interest

Who are some of Nabriva Therapeutics' key competitors?

What other stocks do shareholders of Nabriva Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

Who are Nabriva Therapeutics' key executives?

Nabriva Therapeutics' management team includes the following people:
  • Theodore R. Schroeder, Chief Executive Officer & Director
  • Steven P. Gelone, President & Chief Operating Officer
  • Gary L. Sender, Chief Financial Officer
  • Jennifer Schranz, Chief Medical Officer
  • William Q. Sargent, Vice President-Commercial Strategy & Access

What is Nabriva Therapeutics' stock symbol?

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

Who are Nabriva Therapeutics' major shareholders?

Nabriva Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Kestra Private Wealth Services LLC (0.03%), WINTON GROUP Ltd (0.03%), Morgan Stanley (0.02%), Exane Derivatives (0.01%) and Exane Derivatives (0.01%). Company insiders that own Nabriva Therapeutics stock include Charles A Rowland Jr, Colin Md Broom, Francesco Maria Lavino, Gary Sender, Steven P Gelone and Theodore R Schroeder.
View institutional ownership trends for Nabriva Therapeutics

Which major investors are selling Nabriva Therapeutics stock?

NBRV stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley.
View insider buying and selling activity for Nabriva Therapeutics

Which major investors are buying Nabriva Therapeutics stock?

NBRV stock was acquired by a variety of institutional investors in the last quarter, including Kestra Private Wealth Services LLC, WINTON GROUP Ltd, Exane Derivatives, and Exane Derivatives. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Charles A Rowland Jr, Colin Md Broom, Francesco Maria Lavino, and Theodore R Schroeder.
View insider buying and selling activity for Nabriva Therapeutics

How do I buy shares of Nabriva Therapeutics?

Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nabriva Therapeutics' stock price today?

One share of NBRV stock can currently be purchased for approximately $3.70.

How big of a company is Nabriva Therapeutics?

Nabriva Therapeutics has a market capitalization of $557.87 million and generates $9.48 million in revenue each year. The biotechnology company earns $-82,760,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Nabriva Therapeutics employs 162 workers across the globe.

What is Nabriva Therapeutics' official website?

The official website for Nabriva Therapeutics is www.nabriva.com.

How can I contact Nabriva Therapeutics?

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The biotechnology company can be reached via phone at (531) 649-2000 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.